153 related articles for article (PubMed ID: 23526749)
1. Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Kaste SC; Kaufman RA; Gajjar A; Broniscer A
Pediatr Blood Cancer; 2013 Sep; 60(9):1552-6. PubMed ID: 23526749
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Broniscer A; Baker SD; Wetmore C; Pai Panandiker AS; Huang J; Davidoff AM; Onar-Thomas A; Panetta JC; Chin TK; Merchant TE; Baker JN; Kaste SC; Gajjar A; Stewart CF
Clin Cancer Res; 2013 Jun; 19(11):3050-8. PubMed ID: 23536435
[TBL] [Abstract][Full Text] [Related]
3. Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Patay Z; Merchant TE; Nguyen R; Pierson CR; Onar-Thomas A; Broniscer A
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1295-1305. PubMed ID: 29165288
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
[TBL] [Abstract][Full Text] [Related]
5. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
Sedlacik J; Winchell A; Kocak M; Loeffler RB; Broniscer A; Hillenbrand CM
AJNR Am J Neuroradiol; 2013 Jul; 34(7):1450-5. PubMed ID: 23436052
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Vandetanib plus Everolimus for the Treatment of
Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
8. Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.
Svolos P; Reddick WE; Edwards A; Sykes A; Li Y; Glass JO; Patay Z
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1235-1241. PubMed ID: 28428205
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Cabebe EC; Fisher GA; Sikic BI
Invest New Drugs; 2012 Jun; 30(3):1082-7. PubMed ID: 21404105
[TBL] [Abstract][Full Text] [Related]
14. Diffuse interstitial lung disease linked to vandetanib.
Ernesto S; Arpin D; Nesme P; Pérol M
Clin Lung Cancer; 2012 May; 13(3):236-8. PubMed ID: 22133289
[No Abstract] [Full Text] [Related]
15. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of
Tinkle CL; Duncan EC; Doubrovin M; Han Y; Li Y; Kim H; Broniscer A; Snyder SE; Merchant TE; Shulkin BL
J Nucl Med; 2019 Mar; 60(3):312-319. PubMed ID: 30072503
[TBL] [Abstract][Full Text] [Related]
17. Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas.
Gokce-Samar Z; Beuriat PA; Faure-Conter C; Carrie C; Chabaud S; Claude L; Di Rocco F; Mottolese C; Szathmari A; Chabert C; Frappaz D
Childs Nerv Syst; 2016 Aug; 32(8):1415-23. PubMed ID: 27379495
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
19. Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.
Jackson S; Patay Z; Howarth R; Pai Panandiker AS; Onar-Thomas A; Gajjar A; Broniscer A
J Neurooncol; 2013 Sep; 114(3):339-44. PubMed ID: 23813229
[TBL] [Abstract][Full Text] [Related]
20. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
